Cardiff University | Prifysgol Caerdydd ORCA
Online Research @ Cardiff 
WelshClear Cookie - decide language by browser settings

Oestrogen receptor variant expression as potential selectors for adjuvant endocrine therapy in breast cancer patients [Abstract]

Green, A. R., Paish, E. C., Gee, Julia Margaret Wendy ORCID: https://orcid.org/0000-0001-6483-2015, Nicholson, Robert Ian, Cheung, K. L., Robertson, J. F. R. and Ellis, I. O. 2005. Oestrogen receptor variant expression as potential selectors for adjuvant endocrine therapy in breast cancer patients [Abstract]. Journal of Pathology 205 (S1) , 5A. 10.1002/path.1762

Full text not available from this repository.

Abstract

Disease-free interval differs amongst invasive breast cancer patients, who had not received any prior adjuvant systemic therapy, with oestrogen receptor (ER) positive cancers treated by endocrine therapy at the time of relapse. This suggests the presence of biological factors inherent in tumours which affect responsiveness to subsequent endocrine therapy. ER splice variants result from exon deletions and can repress wild-type receptors and modulate anti-oestrogen activity. We hypothesise ER splice variants contribute to the differences seen with therapeutic response in these patients. We have characterised variant ER expression in primary invasive breast cancer patients that either responded or not responded to endocrine therapy at the time of relapse. Breast tumour cells were isolated from formalin-fixed archival tumour sections using laser microdissection. Total RNA was extracted and expression of ER�, ER�R2-3, ER�R3, ER�R5, ER�1, ER�2 was quantified using real-time PCR. Gene expression was normalised against 18s expression. Expression of ER� wildtype and variants were detected in most breast tumours although levels differed. ER�1 was highly expressed in tumours with low ER� expression. ER�2 was less commonly expressed. An association between disease-free interval and ER variant expression remains to be elucidated although there was a tendency for tumours expressing ER� also expressed ER�R3.

Item Type: Article
Date Type: Publication
Status: Published
Schools: Pharmacy
Subjects: R Medicine > RC Internal medicine > RC0254 Neoplasms. Tumors. Oncology (including Cancer)
R Medicine > RM Therapeutics. Pharmacology
Additional Information: Abstract for The 187th Meeting of the Pathological Society of Great Britain and Ireland, The Robin Brook Centre, St. Bartholomew's Hospital, London, 6–7 January 2005
Publisher: Wiley-Blackwell
ISSN: 1096-9896
Last Modified: 18 Oct 2022 14:18
URI: https://orca.cardiff.ac.uk/id/eprint/17094

Actions (repository staff only)

Edit Item Edit Item